What are the key financial results for the second quarter of 2018?

The 10-Q filing provides detailed financial statements, including the Consolidated Statements of Earnings and Comprehensive Income, which will outline revenue, expenses, and net income for the quarter. Investors should refer to Item 1 of the filing for these specific figures.

What are the main drivers of Bristol Myers Squibb's financial performance in this quarter?

Management's Discussion and Analysis (MD&A) in Item 2 is the primary section to understand the drivers of performance. This typically includes commentary on product sales, research and development investments, and any significant operational events impacting results.

What are the major risks and legal issues facing Bristol Myers Squibb?

Item 1A (Risk Factors) and Item 1 (Legal Proceedings) will detail any significant risks, litigation, or regulatory matters that could impact the company's financial health and future operations.

Are there any significant changes in the company's balance sheet or cash flow?

The Consolidated Balance Sheets and Consolidated Statements of Cash Flows (Item 1) provide the financial position and cash movement details. Reviewing these statements will reveal any material changes in assets, liabilities, equity, or cash generated/used from operating, investing, and financing activities.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q2 FY2018

Summary

Bristol Myers Squibb (BMY) reported its second-quarter results for the period ending June 29, 2018. The company demonstrated continued strong operational performance driven by key products, suggesting a positive trajectory for revenue and profitability. Investors should note the company's ongoing commitment to research and development, which is crucial for its long-term growth prospects and pipeline innovation. The filing indicates a stable financial position, with management focused on strategic execution and navigating the evolving pharmaceutical landscape.

Financial Highlights

58 data points

Beta

Revenue

$5.70B

0.7% Gross Margin

Net Income

$373.00M

0.1% Net Margin

EPS (Diluted)

$0.23

Total Assets

$32.64B

Cash & Equivalents

$5.00B

Free Cash Flow

$859.00M

Financial Statements

Beta

Revenue	$5.70B
Cost of Revenue	$1.63B
Gross Profit	$4.10B
R&D Expenses	$2.44B
SG&A Expenses	$1.13B
Operating Expenses	$5.19B
Interest Expense	$45.00M
Net Income	$373.00M
EPS (Basic)	$0.23
EPS (Diluted)	$0.23
Shares Outstanding (Basic)	1.63B
Shares Outstanding (Diluted)	1.64B

Key Highlights

1The report covers the second quarter of 2018, providing a snapshot of the company's performance mid-year.
2Financial statements, including Consolidated Statements of Earnings, Comprehensive Income, Balance Sheets, and Cash Flows, are presented.
3Management's Discussion and Analysis (MD&A) offers insights into the company's financial condition and operational results.
4Disclosure on market risk and controls and procedures are included, providing transparency on business operations.
5Information on legal proceedings and risk factors highlights potential challenges and uncertainties.
6The filing details unregistered sales of equity securities and the use of proceeds, if any.
7Exhibits are listed, which may contain further supporting documentation for the reported period.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2018

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions